Munich, Germany – Chronic hepatitis B, resulting from infection with the hepatitis B virus (HBV), is an inflammatory liver disease that results in tissue damage. Persistent HBV infection, where the immune system cannot fully eradicate the virus, can lead to continuous liver damage, liver cirrhosis, and even liver cancer. HBV...
Latest News
Ildiko Hammond is exhausted. Not only is caring for her severely disabled daughter a full-time job, it is also financially draining. But yesterday, the Lismore mother of two received some welcome news. Mrs Hammond and about 19,000 other carers of children with profound disabilities will soon qualify for a $550-a-fortnight...
A couple have made a heartfelt appeal for help to get their terminally ill son to America for treatment. Adel and Damien Elliott from Enniskillen were left shattered by the news that both their sons Marc (4) and two-month-old Matthew have the incurable and deadly illness adrenoleukodystrophy, a rare genetic...
Durham, NC – Karen Kump of Elko, Nevada, knew the lump on her right breast should be checked by a doctor when she first noticed it in July 2022. “But my granddaughter was getting married, and I wanted the attention to be on her,” she said. Kump, 78, didn’t know...
The grandparents of a four-year-old Enniskillen boy diagnosed with a rare terminal illness are appealing for public support to help them raise money towards his dietary needs, treatment, hospital trips, and even a possible cure. Marc Elliott is the son of Damien and Adel and brother to six-week-old Matthew. They...
COPENHAGEN, Denmark and BOSTON – Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today announces the successful closing of a US$ 55M Series A financing. The investment was led by Novo Holdings, HealthCap and RA Capital Management. Benny Sorensen, MD, PhD, who served on Hemab’s Board...
COPENHAGEN, Denmark and CAMBRIDGE, Mass. — Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic treatment for the...
LONDON, UK – Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration (FDA) that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukemia (AML). The FDA...
Among patients with hemophilia A who receive primary prophylaxis, quality of life (QoL) may be lower compared with the general population, according to research published in Haemophilia. Among patients with severe hemophilia, prophylaxis with clotting factor replacement therapy is the standard treatment, though patients vary in when they initiate therapy. In...
Adult men with hemophilia B had annual health care costs that totaled more than 25-fold higher than matched controls, demonstrating the burden of this illness in research published in Blood Advances. The study authors used a claims-based algorithm to identify 454 male patients with hemophilia B and compared them to 454...